Pharmacoproteomics Reveals Energy Metabolism Pathways As Therapeutic Targets of Ivermectin in Ovarian Cancer Toward 3P Medical Approaches

Overview

Journal EPMA J

Date 2024 Dec 5

PMID 39635022

Authors

Zhijun Li

Na Li

Marie Louise Ndzie Noah

Qianwen Shao

Xianquan Zhan

Affiliations

Soon will be listed here.

Abstract

Objective: Ovarian cancer is the malignant tumor with the highest mortality rate in the female reproductive system, enormous socio-economic burden, and limited effective drug therapy. There is an urgent need to find novel effective drugs for ovarian cancer therapy. Our previous in vitro studies demonstrate that ivermectin effectively inhibits ovarian cancer cells and affects energy metabolism pathways. This study aims to clarify in vivo mechanisms and therapeutic targets of ivermectin in the treatment of ovarian cancer to establish predictive biomarkers, guide personalized treatments, and improve preventive strategies in the framework of 3P medicine.

Methods: A TOV-21G tumor-bearing mouse model was constructed based on histopathological data and biochemical parameters. TMT-based proteomic analysis was performed on tumor tissues from the different treatment groups. All significantly differentially abundant proteins were characterized by hierarchical clustering, Gene Ontology (GO) enrichment analyses, and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses. In addition, the data were integrated and analyzed with the proteomic data of clinical ovarian cancer tissues from our previous study and the proteomic data of ivermectin intervention in ovarian cancer cells to identify key regulators of ivermectin.

Results: Ivermectin (10 mg/kg) had a significant anti-ovarian cancer effect in mice, with a tumor inhibitory rate of 61.5%. Molecular changes in tumor tissue of ivermectin-treated mice were established, and protein-protein interaction (PPI) analysis showed that the main differential pathway networks included the TCA cycle, propanoate metabolism, 2-0xocarboxyacid metabolism, and other pathways. Integrating our previous clinical ovarian cancer tissue and cell experimental data, this study found that ivermectin significantly interfered with the energy metabolic pathways of ovarian cancer, including glycolysis, TCA cycle, oxidative phosphorylation, and other related pathways.

Conclusions: This study evaluated the anti-ovarian cancer effect in vitro and in vivo, and its specific regulatory effect on energy metabolism. The expressions of drug target molecules in the energy metabolism pathway of ovarian cancer will be used to guide the diagnosis and prevention of ovarian cancer. The significant efficacy of ivermectin will be applied to the treatment of ovarian cancer and personalized medication. This has guiding significance for the clinical diagnosis, treatment, personalized medication, and prognosis evaluation of ovarian cancer.

Supplementary Information: The online version contains supplementary material available at 10.1007/s13167-024-00385-1.

References

Huang Y, Du Y, Zheng Y, Wen C, Zou H, Huang J . Ct-OATP1B3 promotes high-grade serous ovarian cancer metastasis by regulation of fatty acid beta-oxidation and oxidative phosphorylation. Cell Death Dis. 2022; 13(6):556. PMC: 9206684. DOI: 10.1038/s41419-022-05014-1. View

Ye L, Yao X, Xu B, Chen W, Lou H, Tong X . RNA epigenetic modifications in ovarian cancer: The changes, chances, and challenges. Wiley Interdiscip Rev RNA. 2023; 14(5):e1784. DOI: 10.1002/wrna.1784. View

Li N, Li J, Desiderio D, Zhan X . SILAC quantitative proteomics analysis of ivermectin-related proteomic profiling and molecular network alterations in human ovarian cancer cells. J Mass Spectrom. 2020; 56(1):e4659. DOI: 10.1002/jms.4659. View

Li C, Liu F, Shen Y, Tian Y, Han F . Research progress on the mechanism of glycolysis in ovarian cancer. Front Immunol. 2023; 14:1284853. PMC: 10715264. DOI: 10.3389/fimmu.2023.1284853. View

Zuo J, Tang J, Lu M, Zhou Z, Li Y, Tian H . Glycolysis Rate-Limiting Enzymes: Novel Potential Regulators of Rheumatoid Arthritis Pathogenesis. Front Immunol. 2021; 12:779787. PMC: 8651870. DOI: 10.3389/fimmu.2021.779787. View

Sambasivan S . Epithelial ovarian cancer: Review article. Cancer Treat Res Commun. 2022; 33:100629. DOI: 10.1016/j.ctarc.2022.100629. View

Mittica G, Ghisoni E, Giannone G, Genta S, Aglietta M, Sapino A . PARP Inhibitors in Ovarian Cancer. Recent Pat Anticancer Drug Discov. 2018; 13(4):392-410. DOI: 10.2174/1574892813666180305165256. View

Nava G, Madrigal Perez L . Metabolic profile of the Warburg effect as a tool for molecular prognosis and diagnosis of cancer. Expert Rev Mol Diagn. 2022; 22(4):439-447. DOI: 10.1080/14737159.2022.2065196. View

Webb P, Jordan S . Global epidemiology of epithelial ovarian cancer. Nat Rev Clin Oncol. 2024; 21(5):389-400. DOI: 10.1038/s41571-024-00881-3. View

10.

Halma M, Tuszynski J, Marik P . Cancer Metabolism as a Therapeutic Target and Review of Interventions. Nutrients. 2023; 15(19). PMC: 10574675. DOI: 10.3390/nu15194245. View

11.

Kurnit K, Frumovitz M . Primary mucinous ovarian cancer: options for surgery and chemotherapy. Int J Gynecol Cancer. 2022; 32(11):1455-1462. DOI: 10.1136/ijgc-2022-003806. View

12.

Guo Y, Jiang W, Yu W, Niu X, Liu F, Zhou T . Proteomics analysis of asthenozoospermia and identification of glucose-6-phosphate isomerase as an important enzyme for sperm motility. J Proteomics. 2019; 208:103478. DOI: 10.1016/j.jprot.2019.103478. View

13.

Koklesova L, Mazurakova A, Samec M, Kudela E, Biringer K, Kubatka P . Mitochondrial health quality control: measurements and interpretation in the framework of predictive, preventive, and personalized medicine. EPMA J. 2022; 13(2):177-193. PMC: 9096339. DOI: 10.1007/s13167-022-00281-6. View

14.

Liu X, Qiao Y, Ting X, Si W . Isocitrate dehydrogenase 3A, a rate-limiting enzyme of the TCA cycle, promotes hepatocellular carcinoma migration and invasion through regulation of MTA1, a core component of the NuRD complex. Am J Cancer Res. 2020; 10(10):3212-3229. PMC: 7642667. View

15.

Talekar M, Ouyang Q, Goldberg M, Amiji M . Cosilencing of PKM-2 and MDR-1 Sensitizes Multidrug-Resistant Ovarian Cancer Cells to Paclitaxel in a Murine Model of Ovarian Cancer. Mol Cancer Ther. 2015; 14(7):1521-31. PMC: 4497852. DOI: 10.1158/1535-7163.MCT-15-0100. View

16.

Wu Y, Zhang X, Wang Z, Zheng W, Cao H, Shen W . Targeting oxidative phosphorylation as an approach for the treatment of ovarian cancer. Front Oncol. 2022; 12:971479. PMC: 9486401. DOI: 10.3389/fonc.2022.971479. View

17.

Wang L, Tong S, Hu H, Ye F, Li S, Ren H . Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach. J Cell Biochem. 2012; 113(12):3762-72. DOI: 10.1002/jcb.24250. View

18.

Fu X, Zhang Q, Wang Z, Xu Y, Dong Q . CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α. Cell Death Dis. 2024; 15(1):21. PMC: 10776574. DOI: 10.1038/s41419-023-06398-4. View

19.

Konstantinopoulos P, Matulonis U . Clinical and translational advances in ovarian cancer therapy. Nat Cancer. 2023; 4(9):1239-1257. DOI: 10.1038/s43018-023-00617-9. View

20.

Liskova A, Samec M, Koklesova L, Kudela E, Kubatka P, Golubnitschaja O . Mitochondriopathies as a Clue to Systemic Disorders-Analytical Tools and Mitigating Measures in Context of Predictive, Preventive, and Personalized (3P) Medicine. Int J Mol Sci. 2021; 22(4). PMC: 7922866. DOI: 10.3390/ijms22042007. View